Fecal Occult Blood Test (FOBT) Global Market Report 2026

The fecal occult blood test (FOBT) market size has grown strongly in recent years. It will grow from $1.85 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising prevalence of colorectal cancer, growing awareness of preventive health screening, expansion of national cancer screening programs, increasing geriatric population, improvements in diagnostic laboratory infrastructure.

The fecal occult blood test (FOBT) market size is expected to see strong growth in the next few years. It will grow to $2.67 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing demand for non-invasive diagnostic methods, growing adoption of at-home testing solutions, rising healthcare expenditure in emerging markets, expansion of personalized medicine approaches, increasing integration of digital health platforms. Major trends in the forecast period include increasing adoption of immunochemical fobt kits, rising preference for home-based screening tests, growing focus on early colorectal cancer detection, expansion of point-of-care fobt devices, increasing development of high-sensitivity test reagents.

The increasing prevalence and public health impact of colorectal cancer are anticipated to drive the expansion of the fecal occult blood test (FOBT) market in the coming years. Colorectal cancer is a malignancy that originates in the colon or rectum and frequently develops from abnormal growths called polyps. Its incidence is rising due to factors such as sedentary lifestyles, aging populations, and dietary patterns, which elevate the risk of cancer development in the digestive system. The fecal occult blood test (FOBT) aids colorectal cancer screening by identifying hidden blood in stool at an early stage, allowing prompt diagnosis, enhancing treatment outcomes, and slowing disease progression. For example, in February 2025, according to the Office for National Statistics (ONS), a UK government agency, approximately 15,552 deaths from colorectal cancer were recorded in England and Wales in 2023, with preliminary figures for 2024 showing a similar trend, underscoring the substantial disease burden and the increasing demand for early screening and preventive diagnostic tools. Hence, the growing prevalence of colorectal cancer is fueling the expansion of the fecal occult blood test (FOBT) market.

Key companies operating in the fecal occult blood test (FOBT) market are focusing on developing innovative products such as at-home over-the-counter (OTC) FOBT kits to increase early detection rates and improve patient convenience. At-home over-the-counter (OTC) FOBT kits are non-invasive test kits that allow individuals to collect stool samples at home for detecting hidden blood, providing early colorectal cancer screening and greater convenience compared to lab-based tests. For example, in December 2023, DiaCarta Inc., a US-based precision diagnostic company, launched the iColon Fecal Occult Blood Test, an OTC at-home test that enables early detection of blood in stool, clinically relevant for gastrointestinal disorders and colorectal cancer. The iColon test is designed to be user-friendly and non-invasive, allowing patients to collect samples without medical supervision. It combines sensitive detection methods that improve accuracy over traditional guaiac-based FOBTs, reducing false negatives and enabling earlier intervention. Additionally, it supports timely follow-up with healthcare providers if abnormal results are detected, promoting proactive colorectal health management.

In January 2023, SD Biosensor Inc., a South Korea-based healthcare technology company, and SJL Partners LLC, a South Korea-based private equity investment firm, completed the acquisition of Meridian Bioscience Inc. for $1.53 billion. This acquisition was intended to expand the buyers’ global diagnostics presence, broaden their product portfolio, and enhance technological and distribution capabilities within the in vitro diagnostics sector, especially in North America and other strategic markets. Meridian Bioscience Inc. is a US-based life sciences and diagnostics company specializing in the development of fecal occult blood tests (FOBT).

Major companies operating in the fecal occult blood test (fobt) market are F. Hoffmann-La Roche AG, Siemens Healthineers AG, Medline Industries Inc., Quest Diagnostics Incorporated, Sysmex Corporation, Quidel Corporation, Randox Laboratories Ltd., BIOMERICA Inc., Aidian Oy, Meridian Bioscience Inc., CTK Biotech Inc., Eiken Chemical Co. Ltd., Hemosure Inc., Alfa Scientific Designs Inc., AdvaCare Pharma Inc., Biohit Oyj, Immunostics Inc., Apacor Ltd., Humasis Co. Ltd., Firstep Bioresearch Inc., Biopanda Reagents Ltd, Ameritek Inc.

North America was the largest region in the fecal occult blood test (FOBT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal occult blood test (fobt) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fecal occult blood test (fobt) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fecal occult blood test (FOBT) market consists of sales of take-home guaiac kits, lateral-flow immunochemical strips, rapid one-step immunoassay cassettes, flushable reagent pads, stool collection devices, molecular stool tests, and multi-marker combination panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

A fecal occult blood test (FOBT) is a diagnostic procedure that identifies hidden blood in stool, which may indicate bleeding within the digestive tract. It is commonly used to screen for colorectal cancer and other gastrointestinal conditions. The test involves analyzing a small stool sample for traces of blood that are not visible to the naked eye.

The key product types of fecal occult blood tests include guaiac-based fecal occult blood tests, immunochemical fecal occult blood tests, and other variants. Guaiac-based fecal occult blood tests are diagnostic methods that detect hidden blood in stool samples using chemical reactions. Sample types include stool-based and others. Applications include colorectal cancer screening, gastrointestinal bleeding, and other areas, serving hospitals, diagnostic laboratories, clinics, home care settings, and other end-users.

Tariffs on imported diagnostic reagents, testing kits, and laboratory equipment have impacted the fecal occult blood test market by increasing manufacturing and procurement costs, particularly affecting immunochemical and DNA-based test kit segments. Regions such as North America and Europe that rely on imported raw materials and reagents from Asia-Pacific suppliers face higher pricing pressures. Hospitals and diagnostic laboratories are most affected due to bulk procurement needs. However, tariffs are also encouraging local production of diagnostic kits, fostering domestic manufacturing capabilities, and promoting innovation in cost-effective, high-sensitivity screening solutions.

The fecal occult blood test (fobt) market research report is one of a series of new reports that provides fecal occult blood test (fobt) market statistics, including fecal occult blood test (fobt) industry global market size, regional shares, competitors with a fecal occult blood test (fobt) market share, detailed fecal occult blood test (fobt) market segments, market trends and opportunities, and any further data you may need to thrive in the fecal occult blood test (fobt) industry. This fecal occult blood test (fobt) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.